Decreasing maternal myostatin programs adult offspring bone strength in a mouse model of osteogenesis imperfecta.
Decreasing maternal myostatin programs adult offspring bone strength in a mouse model of osteogenesis imperfecta.
复制标题
在成骨不全小鼠模型中,母体肌生长抑制素的减少会影响成年后代的骨强度。
DOI:
10.1073/pnas.1607644113
复制
发表时间:
2016
影响因子:
11.1
通讯作者:
Phillips,CharlotteL
中科院分区:
文献类型:
--
作者:
Oestreich,ArinK;Kamp,WilliamM;McCray,MarcusG;Carleton,StephanieM;Karasseva,Natalia;Lenz,KristinL;Jeong,Youngjae;Daghlas,SalahA;Yao,Xiaomei;Wang,Yong;Pfeiffer,FerrisM;Ellersieck,MarkR;Schulz,LauraC;Phillips,CharlotteL
During fetal development, the uterine environment can have effects on offspring bone architecture and integrity that persist into adulthood; however, the biochemical and molecular mechanisms remain unknown. Myostatin is a negative regulator of muscle mass. Parental myostatin deficiency (Mstntm1Sjl/+) increases muscle mass in wild-type offspring, suggesting an intrauterine programming effect. Here, we hypothesized thatMstntm1Sjl/+dams would also confer increased bone strength. In wild-type offspring, maternal myostatin deficiency altered fetal growth and calvarial collagen content of newborn mice and conferred a lasting impact on bone geometry and biomechanical integrity of offspring at 4 mo of age, the age of peak bone mass. Second, we sought to apply maternal myostatin deficiency to a mouse model with osteogenesis imperfecta (Col1a2oim), a heritable connective tissue disorder caused by abnormalities in the structure and/or synthesis of type I collagen. Femora of maleCol1a2oim/+offspring from natural mating ofMstntm1Sjl/+dams toCol1a2oim/+sires had a 15% increase in torsional ultimate strength, a 29% increase in tensile strength, and a 24% increase in energy to failure compared with age, sex, and genotype-matched offspring from natural mating ofCol1a2oim/+dams toCol1a2oim/+sires. Finally, increased bone biomechanical strength ofCol1a2oim/+offspring that had been transferred intoMstntm1Sjl/+dams as blastocysts demonstrated that the effects of maternal myostatin deficiency were conferred by the postimplantation environment. Thus, targeting the gestational environment, and specifically prenatal myostatin pathways, provides a potential therapeutic window and an approach for treating osteogenesis imperfecta.